Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) have been given an average recommendation of "Moderate Buy" by the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $29.75.

A number of analysts have recently weighed in on the stock. Evercore ISI cut their price objective on shares of Jasper Therapeutics from $50.00 to $20.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. JMP Securities cut their price objective on Jasper Therapeutics from $70.00 to $12.00 and set a "market outperform" rating on the stock in a research report on Tuesday, July 8th. UBS Group cut their price target on shares of Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Oppenheimer lowered their target price on Jasper Therapeutics from $80.00 to $65.00 and set an "outperform" rating on the stock in a research note on Thursday, May 15th. Finally, Cantor Fitzgerald cut Jasper Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, July 7th.

Jasper Therapeutics Stock Performance

JSPR stock opened at $3.33 on Friday. The company's 50 day moving average price is $5.04 and its two-hundred day moving average price is $5.59. Jasper Therapeutics has a one year low of $2.27 and a one year high of $26.05. The company has a market capitalization of $50.02 million, a PE ratio of -0.64 and a beta of 2.69.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.24). On average, research analysts predict that Jasper Therapeutics will post -4.47 EPS for the current year.

Hedge Funds Weigh In On Jasper Therapeutics

A number of hedge funds have recently modified their holdings of JSPR. Wellington Management Group LLP boosted its position in Jasper Therapeutics by 13.9% during the fourth quarter. Wellington Management Group LLP now owns 27,069 shares of the company's stock valued at $579,000 after purchasing an additional 3,310 shares during the last quarter. Deutsche Bank AG raised its holdings in Jasper Therapeutics by 30.0% during the fourth quarter. Deutsche Bank AG now owns 170,695 shares of the company's stock valued at $3,649,000 after buying an additional 39,436 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Jasper Therapeutics by 106.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after buying an additional 3,828 shares during the last quarter. Simplify Asset Management Inc. bought a new position in shares of Jasper Therapeutics in the 4th quarter valued at approximately $428,000. Finally, Soleus Capital Management L.P. boosted its position in Jasper Therapeutics by 11.2% during the fourth quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company's stock worth $31,951,000 after purchasing an additional 150,755 shares during the period. 79.85% of the stock is currently owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.